Prediction Case File
YouTubeEvaluation Complete

SLS SELLAS Life Sciences: Stock Analysis + Monday Predicted Opening Price - 5 Must-Knows πŸ”₯

1 extracted signal Β· 1 resolved Β· 0 still active

StockInvest.us profile imageStockInvest.us29 Jun 2026, 10:37 UTC
Video preview for SLS SELLAS Life Sciences: Stock Analysis + Monday Predicted Opening Price - 5 Must-Knows πŸ”₯
Signals
1
Eligible signals in this source
Open
0
Still being tracked
Resolved
1
Evaluable outcomes
Successful
0
Canonical correct result
Failed
1
Canonical failed result
Resolved success
0%
Open and excluded signals omitted
Source overview

AI-generated source summary

SELLAS Life Sciences Group (SLS) exhibits a bullish short-term and long-term trend, supported by Moving Averages and MACD signals. The stock has shown strong upward momentum, breaking through resistance levels. Analysts have assigned a 'hold/accumulate' rating, with a 'C' general rating and a 'Sell' action. Recent news indicates progress in clinical trials and a strengthened cash position, providing a multi-year runway for commercialization. The stock's price action shows a 73.29% rise from a pivot bottom found 11 days ago, with further upside anticipated until a new top pivot is established. Support levels are identified at $9.36 and $7.94. A breach below these could signal a sell-off. The P/E ratio is a negative -54.27, suggesting the company is not currently profitable and is incurring losses, which could indicate potential bankruptcy risk. Daily volatility is high at 13.04%, and the RSI is 80, indicating an overbought condition and increasing risk. The stock's price movement suggests a target range between $28.89 and $45.71 over the next year. The stock is currently trading at $12.39 with a suggested stop-loss at $11.97 (-3.40%).

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  7. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

StockInvest.us

Tracked signals
1521
Historical success
43.3%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.